⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for b cell lymphoma

Every month we try and update this database with for b cell lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1NCT04418141
Advanced Solid ...
B Cell Lymphoma
CN1
18 Years - 75 YearsCuron Biopharmaceutical (Australia) Co Pty Ltd
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell LymphomaNCT05412290
B Cell Lymphoma
Aggressive Lymp...
Diffuse Large B...
High-grade B-ce...
Transformed Lym...
Follicular Lymp...
Mosunetuzumab
18 Years - Washington University School of Medicine
Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or LymphomaNCT01593696
ALL
B Cell Lymphoma
Leukemia
Large Cell Lymp...
Non-Hodgkin Lym...
Anti-Cluster of...
1 Year - 30 YearsNational Institutes of Health Clinical Center (CC)
Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell LymphomaNCT00880867
B Cell Lymphoma
T Cell Lymphoma
Poly-ICLC
18 Years - Nevada Cancer Institute
BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I)NCT04018248
Diffuse Large B...
Follicular Lymp...
Chronic Lymphoc...
Small Lymphocyt...
B Cell Lymphoma
Marginal Zone L...
Waldenstrom Mac...
Peripheral T Ce...
BR101801 (Phase...
BR101801 (Phase...
18 Years - Boryung Pharmaceutical Co., Ltd
Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell MalignanciesNCT03366350
Acute Lymphobla...
B Cell Lymphoma
Allogeneic hema...
- 70 YearsWuhan Sian Medical Technology Co., Ltd
A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and LymphomaNCT03398967
B Cell Leukemia
B Cell Lymphoma
Universal Dual ...
12 Years - 70 YearsChinese PLA General Hospital
CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.NCT03146533
B Cell Lymphoma
Fludarabine
Cyclophosphamid...
CD19 CART
18 Years - 70 YearsShenzhen Second People's Hospital
A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and LymphomaNCT03398967
B Cell Leukemia
B Cell Lymphoma
Universal Dual ...
12 Years - 70 YearsChinese PLA General Hospital
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell LymphomaNCT05412290
B Cell Lymphoma
Aggressive Lymp...
Diffuse Large B...
High-grade B-ce...
Transformed Lym...
Follicular Lymp...
Mosunetuzumab
18 Years - Washington University School of Medicine
Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell MalignanciesNCT04008251
Acute Lymphobla...
B Cell Lymphoma
Second generati...
14 Years - 70 YearsWuhan Sian Medical Technology Co., Ltd
Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell LymphomaNCT03995147
B Cell Lymphoma
Lymphoma
Lymphoma, B-Cel...
Diffuse Large B...
High-grade B-ce...
Pembrolizumab
R-CHOP Protocol
18 Years - University of Chicago
Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin IdiotypeNCT00001572
B Cell Lymphoma
Follicular Lymp...
Neoplasm
Id-KLH Vaccine
QS-21 (Stimulat...
18 Years - National Institutes of Health Clinical Center (CC)
Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study AnalysisNCT06058858
Cytomegalovirus...
Acute Leukemia
B Cell Lymphoma
1 Year - 100 YearsAssistance Publique - Hôpitaux de Paris
The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell LymphomaNCT03101709
B Cell Lymphoma
Cyclophosphamid...
Fludarabine
CART-19
18 Years - 70 YearsHenan Cancer Hospital
A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma PatientsNCT03670888
B Cell Lymphoma
JHL1101
Rituximab
18 Years - 75 YearsJHL Biotech, Inc.
CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell MalignanciesNCT04156178
B Cell Lymphoma
B Cell Leukemia
CD20-CD19 cCAR ...
- iCell Gene Therapeutics
Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell LymphomaNCT06415708
B Cell Lymphoma
Obinutuzumab Co...
18 Years - Institute of Hematology & Blood Diseases Hospital, China
A Clinical Research of CD22-Targeted CAR-T in B Cell MalignanciesNCT03999697
Diffuse Large B...
Follicular Lymp...
Primary Cutaneo...
Extranodal Marg...
Mantle Cell Lym...
Plasma Cell Neo...
B Cell Lymphoma
Autologous chim...
3 Years - 70 YearsPersonGen BioTherapeutics (Suzhou) Co., Ltd.
Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With ChemotherapyNCT00038571
Lymphoma, B-Cel...
PS341 (Bortezom...
17 Years - M.D. Anderson Cancer Center
Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell MalignanciesNCT03366324
Acute Lymphobla...
B Cell Lymphoma
Second generati...
Hematological s...
- 70 YearsWuhan Sian Medical Technology Co., Ltd
Induced-T Cell Like NK Cells for B Cell MalignanciesNCT04747093
B Cell Leukemia
B Cell Lymphoma
B-cell Acute Ly...
B-cell Lymphoma...
B-cell Lymphoma...
CAR-ITNK cells
18 Years - 65 YearsNanfang Hospital, Southern Medical University
Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma.NCT03929107
B Cell Lymphoma
Interleukin-7 a...
18 Years - 75 YearsFirst Affiliated Hospital of Zhejiang University
A Study of SHR-A1912 for Injection in Patients With B Cell LymphomasNCT05113069
B Cell Lymphoma
SHR-A1912
18 Years - Shanghai Hengrui Pharmaceutical Co., Ltd.
ThisCART19A for B-NHL Relapsed After Auto-CAR TNCT05691153
CAR
B Cell Lymphoma
Relapsed Non-Ho...
ThisCART19A wit...
ThisCART19A wit...
18 Years - 75 YearsThe First Affiliated Hospital of Soochow University
Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell LymphomaNCT06180174
B Cell Lymphoma
Non Hodgkin Lym...
MC-1-50
18 Years - Chongqing Precision Biotech Co., Ltd
Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell LymphomaNCT06415708
B Cell Lymphoma
Obinutuzumab Co...
18 Years - Institute of Hematology & Blood Diseases Hospital, China
Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell LymphomaNCT00880867
B Cell Lymphoma
T Cell Lymphoma
Poly-ICLC
18 Years - Nevada Cancer Institute
A Study of SHR-A1912 for Injection in Patients With B Cell LymphomasNCT05113069
B Cell Lymphoma
SHR-A1912
18 Years - Shanghai Hengrui Pharmaceutical Co., Ltd.
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell LymphomaNCT06213311
B Cell Lymphoma
Glofitamab
Obinutuzumab
Axi-cel
18 Years - M.D. Anderson Cancer Center
CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.NCT03146533
B Cell Lymphoma
Fludarabine
Cyclophosphamid...
CD19 CART
18 Years - 70 YearsShenzhen Second People's Hospital
Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell LymphomasNCT02247609
B-cell Lymphoma...
Anti-CD19 CAR T...
18 Years - Peking University
A Combination of Rituximab and Varlilumab Immunotherapy in Patients With B-cell LymphomaNCT03307746
B Cell Lymphoma
Varlilumab
16 Years - University Hospital Southampton NHS Foundation Trust
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or LymphomasNCT05415098
Nasopharyngeal ...
Castrate Resist...
Gastric Cancer
Ovarian Clear C...
Mesothelioma
Sarcoma
Non Hodgkin Lym...
B Cell Lymphoma
Epithelioid Sar...
APG-5918
18 Years - Ascentage Pharma Group Inc.
Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study AnalysisNCT06058858
Cytomegalovirus...
Acute Leukemia
B Cell Lymphoma
1 Year - 100 YearsAssistance Publique - Hôpitaux de Paris
Association of Velcade to R-CHOP in the Treatment of B Cell LymphomaNCT00169468
B Cell Lymphoma
Rituximab -CHOP...
18 Years - 80 YearsLymphoma Study Association
CD22-CAR T Cells in Children and Young Adults With B Cell MalignanciesNCT04088864
B Cell Lymphoma
Acute Lymphobla...
Lymphoma
Fludarabine
Cyclophosphamid...
Autologous CD22...
1 Year - 30 YearsStanford University
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen VaccinesNCT00001512
B Cell Lymphoma
Follicular Lymp...
Lymphoma
Id-KLH Vaccine
GM-CSF
18 Years - National Institutes of Health Clinical Center (CC)
A Study in Leukemia Patients With KaronudibNCT04077307
Leukemia
Karonudib
18 Years - 75 YearsThomas Helleday Foundation
CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.NCT02132624
B Cell Lymphoma
B Cell Leukemia
Autologous 3rd ...
18 Years - Uppsala University
CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic LeukemiaNCT03854994
B Cell Lymphoma
B-cell Acute Ly...
Anti-CD19 CAR-T...
18 Years - Yan'an Affiliated Hospital of Kunming Medical University
Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell LymphomaNCT02898259
B Cell Lymphoma
Lymphoma
Ixazomib
Lenalidomide
Rituximab
18 Years - Case Comprehensive Cancer Center
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)NCT01435720
Multiple Myelom...
Multiple Myelom...
Mantle Cell Lym...
Diffuse Large B...
Other B Cell Ly...
Plasma Cell Leu...
SNS01-T
SNS01-T
SNS01-T
SNS01-T
18 Years - Senesco Technologies, Inc.
Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin IdiotypeNCT00001572
B Cell Lymphoma
Follicular Lymp...
Neoplasm
Id-KLH Vaccine
QS-21 (Stimulat...
18 Years - National Institutes of Health Clinical Center (CC)
CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)NCT06002659
B-cell Lymphoma
CAR20(NAP)-T
Cyclophosphamid...
Fludarabine
- Uppsala University
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell LymphomaNCT04782193
B Cell Lymphoma
CD19 and CD22 t...
2 Years - 75 YearsChongqing Precision Biotech Co., Ltd
A Study of SHR-A1912 for Injection in Patients With B Cell LymphomasNCT05113069
B Cell Lymphoma
SHR-A1912
18 Years - Shanghai Hengrui Pharmaceutical Co., Ltd.
Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic LeukemiaNCT04289220
B Cell Lymphoma
B-cell Acute Ly...
Anti-CD19 CAR-T...
18 Years - 70 YearsYan'an Affiliated Hospital of Kunming Medical University
Treatment of Aggressive Localized LymphomaNCT00841945
B Cell Lymphoma
rituximab
doxorubicin
vincristine
prednisone
radiotherapy
18 Years - 75 YearsFrench Innovative Leukemia Organisation
CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell MalignanciesNCT04156243
B Cell Lymphoma
B Cell Leukemia
CD19 CARvac T c...
- iCell Gene Therapeutics
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell LymphomaNCT06213311
B Cell Lymphoma
Glofitamab
Obinutuzumab
Axi-cel
18 Years - M.D. Anderson Cancer Center
Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or B Cell LymphomasNCT01799083
Solid Tumors
B Cell Lymphoma
Decitabine
cytokine-induce...
18 Years - 85 YearsChinese PLA General Hospital
Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or LymphomaNCT01593696
ALL
B Cell Lymphoma
Leukemia
Large Cell Lymp...
Non-Hodgkin Lym...
Anti-Cluster of...
1 Year - 30 YearsNational Institutes of Health Clinical Center (CC)
A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell LymphomaNCT00001271
B Cell Lymphoma
IgG-RFB4-SMPT-d...
- National Institutes of Health Clinical Center (CC)
Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin IdiotypeNCT00001572
B Cell Lymphoma
Follicular Lymp...
Neoplasm
Id-KLH Vaccine
QS-21 (Stimulat...
18 Years - National Institutes of Health Clinical Center (CC)
Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin IdiotypeNCT00001572
B Cell Lymphoma
Follicular Lymp...
Neoplasm
Id-KLH Vaccine
QS-21 (Stimulat...
18 Years - National Institutes of Health Clinical Center (CC)
CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLLNCT00586391
B Cell Lymphoma
Chronic Lymphoc...
Acute Lymphocyt...
CD19CAR-28-zeta...
Ipilimumab
- Baylor College of Medicine
Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell MalignanciesNCT03366324
Acute Lymphobla...
B Cell Lymphoma
Second generati...
Hematological s...
- 70 YearsWuhan Sian Medical Technology Co., Ltd
Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell MalignanciesNCT04007978
B Cell Lymphoma
Acute Lymphobla...
Third generatio...
14 Years - 70 YearsWuhan Union Hospital, China
CD19-targeting CAR T Cells for B Cell LymphomaNCT02547948
B Cell Lymphoma
CD19-targeting ...
18 Years - 80 YearsFuda Cancer Hospital, Guangzhou
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant TumorsNCT03302403
B Cell Lymphoma
B Cell Leukemia
Myeloma
Hepatocellular ...
Pancreatic Carc...
Adenocarcinoma ...
CAR-CD19 T cell
CAR-BCMA T cell
CAR-GPC3 T cell
CAR-CLD18 T cel...
Fludarabine
Cyclophosphamid...
18 Years - 75 YearsFirst Affiliated Hospital of Wenzhou Medical University
A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid MalignanciesNCT00741871
Lymphoma, Malig...
Hodgkin's Lymph...
B Cell Lymphoma
SB1518
18 Years - S*BIO
Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple MyelomaNCT01148108
Mantle Cell Lym...
B Cell Lymphoma
Multiple Myelom...
Canfosfamide HC...
18 Years - Telik
A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and LymphomaNCT03166878
B Cell Leukemia
B Cell Lymphoma
UCART019
12 Years - 75 YearsChinese PLA General Hospital
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or LymphomasNCT05415098
Nasopharyngeal ...
Castrate Resist...
Gastric Cancer
Ovarian Clear C...
Mesothelioma
Sarcoma
Non Hodgkin Lym...
B Cell Lymphoma
Epithelioid Sar...
APG-5918
18 Years - Ascentage Pharma Group Inc.
CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell MalignanciesNCT04156243
B Cell Lymphoma
B Cell Leukemia
CD19 CARvac T c...
- iCell Gene Therapeutics
A Phase II Study of the FIL on Elderly Frail Patients With DLBCLNCT02955823
Diffuse Large B...
Rituximab-Dexam...
70 Years - Fondazione Italiana Linfomi - ETS
CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell MalignanciesNCT02965092
Acute Lymphobla...
B Cell Lymphoma
Second generati...
- 70 YearsWuhan Sian Medical Technology Co., Ltd
Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell LymphomaNCT03258047
B Cell Lymphoma
CAR-T
18 Years - First Affiliated Hospital of Zhejiang University
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: